Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages 259-262

  Fuchs, Jonathan D ^a,b   Sobieszczyk, Magdalena E ^c   Madenwald, Tamra ^d   Grove, Doug ^e   Karuna, Shelly T ^d   Andrasik, Michele ^d   Sherwat, Adam ^f   Broder, Gail ^d   Mayer, Kenneth ^g   Koblin, Beryl ^h   Hammer, Scott ^c  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d HIV Vaccine Trials Network   (United States)

^e USA   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h NEW YORK BLOOD CENTER   (United States)

Author keywords

Clinical trials; Good participatory practice; HIV prevention; HIV vaccines; Preexposure prophylaxis

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH INSURANCE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION;

ADENINE; ADOLESCENT; ADULT; AIDS VACCINES; ANTI-HIV AGENTS; DEOXYCYTIDINE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INTENTION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; QUESTIONNAIRES; RESEARCH DESIGN; YOUNG ADULT;

EID: 84880199858     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318296df94     Document Type: Article

References (22)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N EnglJ Med. 2010; 363:2587-2599.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174
3. Erratum, Science 2011;333:524.
4. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preex-posure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
8. AVAC/ UNAIDS. Good Participatory Practice: Guidelines for Biomed-ical HIV Prevention Trials. Geneva, Switzerland: AVAC/UNAIDS; 2011.
9. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47:241-247.
10. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77-83.
11. Krakower DS, Mimiaga MJ, Rosenberger JG, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7:e33119.
12. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
13. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.
14. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm312210.html. Accessed July 16, 2012.
15. Underhill K, Operario D, Mimiaga MJ, et al. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7: 210-219.
16. Prejean J, An Q, Mermin J, et al. Esitmated HIV incidence in the United States, 2006-2009. PloS One. 2011;6:e17502.
17. Koblin B, Mayer K, Eshelman S, et al. Correlates of HIV incidence among black men who have sex with men in 6 U.S. cities (HPTN 061). [MOAC0106]. Paper presented at: XIX International AIDS Conference; 2012; Washington DC.
18. Mayer K, Wang L, Koblin B, et al. An evolving concentrated epidemic: comparison of socioeconomic, behavioural and biological factors among newly diagnosed, previously diagnosed and HIV-negative black men who have sex with men in six US cities (HPTN 061) [MOAC0105]. Paper presented at: XIX International AIDS Conference; 2012; Washington DC.
19. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One. 2012;7:e40603.
20. Leibowitz AA, Parker KB, Rotherram-Borus MJ. A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health. 2011; 101:982-985.
21. Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med. 2012;157:490-497.
22. Cohen M., McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. Clin Trials. 2012;9:340-347. Diseases